China Nuokang Bio-Pharma, a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, has announced that two of its product pipeline candidates recently advanced through the next respective stages of the State Food and Drug Administration (SFDA) review process.

The Company provides a diversified portfolio of products across more than 2,400 hospitals in China. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention.

Company's Chairman and CEO BaiZhong Xue commented, "We are pleased with today's news that our two product candidates are moving forward as planned. The technical review of Kaitong was completed successfully and we will continue to work closely with Jilin Yuhua to obtain the manufacturing license as expeditiously as possible, with our goal still being to receive the license by the end of this year. Once the license is received, we are well prepared to quickly and effectively launch the product across our distribution network."